九典制药(300705) - 九典制药调研活动信息

Financial Performance - In Q1 2023, the company achieved operating revenue of 5.02 billion CNY, a year-on-year increase of 11.76% [1] - The net profit attributable to shareholders was 7,689.05 million CNY, reflecting a growth of 37.39% compared to the same period last year [1] - The net profit after deducting non-recurring gains and losses was 6,895.18 million CNY, up by 26.57% year-on-year [1] Product Sales Breakdown - Sales revenue from the main product, Losofen Sodium Gel, was 246 million CNY, a decrease of 5.64% from 261 million CNY in Q1 2022 [2] - Oral formulations generated sales revenue of 153 million CNY, showing a year-on-year growth of 26.85% [2] - Raw materials achieved sales revenue of 31.87 million CNY, with a year-on-year increase of 39.91% [2] - Pharmaceutical excipients reported sales revenue of 49.22 million CNY, up by 53.15% year-on-year [2] - Plant extracts and others generated sales revenue of 16.77 million CNY, reflecting a growth of 35.13% [2] Market Share and Product Structure - The proportion of Losofen in total revenue decreased from 58.13% to 49.08%, while oral formulations' share increased from 26.81% to 30.34% [2] - The overall gross margin for Q1 2023 was 74.91%, down from 79.1% in the previous year, attributed to changes in product structure [2] Clinical Development and Future Products - The company is actively developing multiple external use formulations, with several products in clinical trials [3] - The market for external patch agents was approximately 15 billion CNY in 2020, growing to about 18 billion CNY in 2021, with a growth rate of around 20% [3] - The company plans to invest in R&D, with expectations of approximately 10 new products being approved annually over the next 2-3 years [4]